Novo Nordisk announced a new multi-month subscription program for FDA-approved Wegovy, offering eligible self-pay patients more predictable pricing through select telehealth partners including Ro, WeightWatchers, and LifeMD. Longer subscriptions lower the monthly cost, with the company saying savings can reach up to $1,200 per year for the injection.

As discussed in an earlier JCS/T2D post, the company’s push for leaders with over-the-counter and consumer-health experience did not point to Wegovy going OTC. It pointed to something more practical: building stronger consumer-facing access models for prescription obesity treatment. Today’s announcement fits that interpretation very well.

This also shows Novo intends to compete more directly with Eli Lilly in the growing market for consumer-oriented obesity care. Instead of relying only on traditional insurance and pharmacy channels, Novo is making a clearer play for patients who want predictable out-of-pocket pricing and telehealth-based access to authentic, FDA-approved treatment.

Sources

Novo Nordisk Press Release
Wegovy Will Not Go OTC: What the Sources Actually Say